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Problem
Group B Streptococcus (GBS) is a leading cause of neonatal morbidity and
mortality. We tested the hypothesis that the choriodecidua plays a role
in GBS-stimulated human beta defensin(HBD)-2 increases in amnion
cells through a secreted factor of choriodecidual origin.
Method of study
Human amnion epithelial cells were treated with choriodecidual GBS-
conditioned medium, live GBS, lipoteichoic acid (LTA), or lipopolysac-
charide (LPS), with and without IL-1 inhibitors.
Results
Choriodecidual tissue punches released IL-1a and IL-1b in response to
GBS and this medium significantly stimulated release of HBD-2 by
amnion cell cultures. Inhibitors of IL-1 significantly impaired the release
of HBD-2 from amnion cells treated with GBS choriodecidual condi-
tioned medium. Direct stimulation of amnion cells with GBS, LTA, or
LPS did not increase HBD-2 release.
Conclusion
Paracrine signaling involving IL-1 of choriodecidual origin is likely a
critical driver for amnion HBD-2 increases in response to GBS infection
of extraplacental membranes.
Introduction
Streptococcus agalactiae or group B Streptococcus (GBS)
is the leading cause of infectious neonatal morbidity
and mortality in the USA.1 GBS in the gravid female
reproductive tract are associated with adverse birth
outcomes such as sepsis and meningitis. The ascend-
ing pathway of infection begins with colonization of
the vagina. GBS then passes through the cervix and
enters the uterine cavity where it can cross the
extraplacental membranes and infect the neonate.
Despite the importance of the extraplacental
membranes, the mechanisms by which GBS colonizes
the membranes and causes infection remain poorly
understood.
Human beta defensins (HBDs) are an important
part of the innate immune system and play critical
roles responding to infectious microorganisms.2–4
HBDs are expressed throughout the reproductive
tract, including the extraplacental membranes.5
HBDs are considered a first defense during preg-
nancy because they can kill bacteria directly through
membrane disruption, pore formation in the mem-
brane wall, and polarization.2,3,6,7 Furthermore,
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HBDs can promote chemotaxis of immune cells.
HBD-2 has been shown to be higher in amniotic
fluid from women with intrauterine microbial infec-
tion compared to women without intrauterine infec-
tion.8 In addition, HBD-2 concentrations in second
trimester amniotic fluid have been positively corre-
lated with preterm premature rupture of the extra-
placental membranes.9 However, infants born
preterm had lower HBD-2 levels measured in cord
blood compared to term neonates.10 Infants that suf-
fered from late onset sepsis tended to have lower
levels of HBD-2 in cord blood suggesting HBD-2 is
critical for effectively fighting infections. Despite the
importance of HBD-2 for pregnancy-related infec-
tions, few studies have looked at potential stimuli
and mechanisms governing HBD-2 expression in the
extraplacental membranes and amnion epithelial
cells. Pathogens increase HBD-2 in ex vivo extraplac-
ental membranes models, yet little is known about
how the pathogens are interacting with the tissue or
which cells are primarily responsible for the HBD-2
production.11–13 In addition, recombinant IL-1b has
been shown to stimulate HBD-2 secretion in amnion
epithelial cell cultures.14
Recently, we demonstrated in an in vitro two-com-
partment model of full thickness human extraplac-
ental membranes that HBD-2 is stimulated in the
amnion epithelial cells following GBS inoculation on
the decidual side of the membranes.15 No bacteria
were observed invading or crossing the tissue, sug-
gesting a trans-tissue signaling mechanism. Here, we
utilized separated extraplacental membranes co-cul-
tured with GBS to test our hypothesis that the cho-
riodecidua plays a necessary role in GBS-stimulated
HBD-2 increases in amnion epithelial cells through a
secreted factor of choriodecidual origin. Moreover,
we provide evidence that IL-1a and IL-1b are the
choriodecidual signaling molecules critical for the
HBD-2 response in amnion epithelial cells.
Materials and methods
Reagents and materials
The GBS strain used in this study (A909, construct
RS020, a gift from Amanda Jones, University of
Washington) was initially isolated from a septic new-
born.16 GBS was grown at 37°C in culture using
Todd Hewitt Broth (THB; Becton-Dickinson, Franklin
Lakes, NJ, USA) or on sheep’s blood agar plates
(Blood Agar Base #2; Remel, Lenexa, KS, USA and
BBL defibrinated sheep blood, Franklin Lakes, NJ,
USA) with 5 lg/mL erythromycin (Hemostat Labs,
Dixon, CA, USA). Media (DMEM catalog # 21063
and DMEM:F12 catalog #11039), buffers, fetal bovine
serum (FBS; catalog #10438), trypsin-EDTA (catalog
#25200), and penicillin/streptomycin (pen/strep; cat-
alog #15140) were from Gibco (Grand Island, NY,
USA). Epidermal growth factor (EGF) and recombi-
nant cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a) were
from Peprotech (Rocky Hill, NJ, USA). Lipoteichoic
acid (LTA) from Staphylococcus aureus, IL-1b neutraliz-
ing antibody, and IgA isotype control were from
Invivogen (San Diego, CA, USA). Lipopolysaccaride
(LPS) from Salmonella typhimurium was from List Bio-
logical Laboratories (Campbell, CA, USA). IL-1Ra
was from Sigma-Aldrich (Saint Louis, MO, USA).
Culture of extraplacental choriodecidual
membranes
According to previously published methods, human
extraplacental membranes were collected from
healthy, non-smoking, singleton pregnancies under-
going scheduled cesarean delivery prior to onset of
labor at the University of Michigan Von Voigtlander
Women’s Hospital Birth Center.15 The University of
Michigan Institutional Review Board approved this
research (IRBMED#HUM0037054).
Membranes were transported to the lab in Dul-
becco’s phosphate-buffered saline (DPBS) following
delivery and rinsed with medium to remove blood
clots. Membranes were then blunt dissected to sepa-
rate the choriodecidua from the amnion. After
dissection, the choriodecidua was punched using a
12-mm biopsy punch. Tissue punches were placed in
12-well plates with 1 mL medium containing Dul-
becco’s modified Eagle’s medium (DMEM) supple-
mented with 1% FBS and pen/strep. Cultures were
incubated at 37°C and 5% CO2. After 4 hr, the med-
ium was exchanged for DMEM/1% FBS without
antibiotics. Treatments were balanced across subjects
with tissue punches from each woman assigned to
each treatment, including control cultures that were
not exposed to GBS or other treatments.
GBS coculture with extraplacental choriodecidual
membranes
GBS in early exponential growth phase was diluted
with DMEM/1% FBS to an estimated 1 9 106
colony-forming units/mL (CFU/mL). Inoculant
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concentrations were validated by overnight growth
on 5% sheep blood agar with erythromycin. GBS
was heat killed by incubating bacterial culture at
70°C for 15 min. Lack of viability was confirmed by
plating GBS on 5% sheep blood agar. LTA and LPS
treatments were made in DMEM/1% FBS. Following
a 24-hr acclimation, the medium of the choriodeci-
dual punches was replaced with 1 mL GBS inoculant
(~1 9 106 CFU/mL), LTA (1 lg/mL), LPS (100 ng/
mL), or fresh DMEM/1%FBS (control). Following
24 hr of incubation with GBS, medium from the
choriodecidual punches was filtered through a 0.2-
lm pore filter to remove the bacteria, and then
stored at 80°C: This medium is referred to as GBS
conditioned choriodecidual medium in this study.
Medium from choriodecidual punches treated with
LTA or LPS for 24 hr was also 0.2 lm filtered and
then stored at 80°C: This medium is referred to as
LTA or LPS conditioned choriodecidual medium.
Coculture experiments were conducted in triplicate
using extraplacental membranes from a minimum of
seven women.
Amnion epithelial cell isolation
Amnion epithelial cells were isolated from the same
membranes used for choriodecidual punch cultures,
using methods adapted from three protocols.17–19
Primary isolated amnion epithelial cells instead of
amnion tissue explants were used to ensure cell type
and cell number across experiments. Briefly, blunt-
dissected amnion was digested with 0.25% trypsin-
EDTA at 37°C for 30 min. Amnion tissue pieces
were transferred to fresh trypsin-EDTA and the
digestion was repeated. Following each digestion,
the trypsin-EDTA was neutralized in the digest with
medium (DMEM:F12) supplemented with 10% FBS
and pen/strep. Cells were pelleted by centrifugation
at 128 g for 5 min, suspended in medium, repel-
leted, and resuspended in medium containing EGF
(DMEM:F12 supplemented with 10% FBS, pen/
strep, and 10 ng/mL EGF). Amnion epithelial cells
were plated at 500,000 cells/well (12-well plates) in
1 mL medium, and grown to 70–80% confluence.
Medium was changed 2 days after seeding, and cells
were treated on day 3.
Amnion epithelial cells were treated with either
GBS choriodecidual conditioned medium, LTA
(10 lg/mL), LPS (100 ng/mL), live GBS
(~1 9 106 CFU/mL), or one of the following recom-
binant cytokines: IL-1a (1 ng/mL), IL-1b (1 ng/mL),
IL-6 (100 ng/mL), IL-8 (100 ng/mL), IL-17 (100 ng/
mL), or TNF-a (100 ng/mL). In addition, cells were
untreated (controls), treated with increasing concen-
trations of IL-1a (12.5–1000 pg/mL), IL-1b (12.5–
1000 pg/mL), or co-treated with IL-1a + IL-1b. Cells
were incubated with treatments for 24 hr. The med-
ium used for these amnion epithelial cell treatments
was the same as that used with choriodecidual
punches (DMEM supplemented with 1% FBS and
pen/strep), except that no pen/strep antibiotic was
included for cultures with live GBS. No changes in
cellular morphology, cytokine secretion, or HBD-2
secretion were noted with the medium change.
Experiments were conducted in triplicate using
extraplacental membranes from a minimum of five
women.
IL-1 inhibitors
To inhibit IL-1 activity, amnion epithelial cells were
treated with GBS choriodecidual conditioned med-
ium for 24 hr with and without IL-1b neutralizing
antibody (1000 ng/mL), IgA isotype control
(1000 ng/mL), or IL-1 receptor antagonist (IL-1Ra;
100 ng/mL; 5.8 nM). IL-1b neutralizing antibody
was incubated with the GBS choriodecidual condi-
tioned medium for 30 min prior to incubation with
the amnion epithelial cells. The concentration used
for IL-1b neutralizing antibody and IL-1Ra was
determined by concentration-response curves gen-
erated by treating amnion epithelial cells with
1 ng/mL IL-1a or IL-1b and increasing concentra-
tions of IL-1b neutralizing antibody or IL-1Ra (Figs
S1 and S2). Reported Kd values for IL-1Ra range
from 0.2 to 14 nM.20,21 Experiments were con-
ducted in triplicate using amnion epithelial cells
from five women.
Cytokine and HBD ELISAs
HBD-2 concentrations in GBS choriodecidual condi-
tioned medium were measured using a commercially
available enzyme-linked immunosorbant assay
(ELISA) kit according to manufacturer’s instructions
(Peprotech). The HBD-2 ELISA detection range was
16–2000 pg/mL. Cytokine concentrations in GBS
choriodecidual conditioned medium and amnion
epithelial cell medium were measured by the Uni-
versity of Michigan Immunology Core using com-
mercially available ELISA kits (R&D Systems,
Minneapolis, MN, USA). Cytokine detection ranges
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were as follows: 7.81–500 pg/mL for IL-1a; 2.91–
2500 pg/mL for IL-1b; 9.38–125,000 pg/mL for IL-6;
31.2–2000 pg/mL for IL-8; and 15.6–5000 pg/mL for
TNF-a. Cytokine and HBD-2 concentrations are
reported as pg or ng protein/mL medium.
Statistical analysis
Data are expressed as mean  S.E.M. and were ana-
lyzed using GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA) or SigmaStat 3.5
software (SigmaStat Software, San Jose, CA, USA).
ANOVAs with Tukey’s post hoc test were performed. Data
were considered significant if the P value was <0.05.
When values were below the ELISA kit limit of detec-
tion (LOD), values were transformed to LOD/√2 prior
to statistical analysis.22 For HBD-2 assays, no-treat-
ment controls, LTA and LPS treatment generally fell
below the LOD, while GBS choriodecidual condi-
tioned medium treatment was above the LOD. Cyto-
kine values for all treatment conditions generally fell
above the LOD.
Results
GBS infection of the choriodecidua induces HBD-2
expression in amnion epithelial cells via paracrine
signaling
To determine whether choriodecidua secretes fac-
tors that stimulate HBD-2 production in amnion
epithelial cells, GBS was applied to choriodecidual
punch cultures that had been stripped from the
amnion, and the GBS choriodecidual conditioned
medium was added to the amnion epithelial cell
cultures. Amnion epithelial cells exposed to the
GBS choriodecidual conditioned medium for 24 hr
showed a robust (11.2-fold) increase in HBD-2
release (Fig. 1; P < 0.05) compared to amnion epi-
thelial cells exposed to control choriodecidual con-
ditioned medium. LTA and LPS were also used to
determine whether a similar host response could
be provoked by bacterial cell wall/membrane com-
ponents and to determine whether host response
was pathogen specific. In contrast to live GBS, nei-
ther LTA choriodecidual conditioned medium nor
LPS choriodecidual conditioned medium stimulated
release of HBD-2 from amnion epithelial cells sug-
gesting the importance of the whole bacteria to
stimulate the host response. Furthermore, amnion
epithelial cells directly stimulated with live GBS,
LTA, or LPS did not exhibit an increased HBD-2
response. HBD-2 was not detected in choriodecidu-
al medium alone (data not shown), indicating that
the HBD-2 increases observed with GBS chorio-
decidual conditioned medium were the result of
HBD-2 secretion from amnion epithelial cells in
culture.
GBS is a potent stimulant for choriodecidual
cytokines
Preliminary experiments demonstrated that amnion
epithelial cells did not release cytokines when stimu-
lated with GBS directly or filtered GBS supernatant
(data not shown). Cytokines were then measured in
the medium of cultured choriodecidual punches
exposed to pathogenic stimuli, to identify cytokines
that may contribute to the HBD-2 response in
amnion epithelial cells. First, heat-killed GBS and
live GBS were compared for stimulation of IL-1b
and TNF-a release. Heat-killed GBS failed to stimu-
late secretion of IL-1b or TNF-a from choriodecidual
punches, in contrast to live GBS, which elicited a
Fig. 1 HBD-2 release in human amnion epithelial cell cultures treated
directly with pathogenic stimuli (live GBS, LTA, or LPS) or with
choriodecidual (CD) conditioned medium generated by culturing CD
tissue punches with live GBS, LTA, or LPS for 24 hr. HBD-2 protein in
the medium was measured by ELISA. Columns are mean  S.E.M.
(N = 24 women for GBS CD conditioned medium, N = 5 women for
live GBS, and N = 7 women for remaining treatment groups). The
asterisk (*) represents a significant difference between treatment and
control when compared by Tukey’s post hoc test following ANOVA
(P < 0.05).
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strong IL-1b (287.2  44.7 pg/mL) and TNF-a
(1969  456.7 pg/mL) response (Fig. 2; P < 0.05).
Additional cytokines were then probed to compare
stimulated release by live GBS, LTA, and LPS. Live
GBS significantly increased IL-1a (38.5-fold), IL-1b
(71.1-fold), TNF-a (10.2-fold), IL-6 (4.5-fold), and
IL-8 (2.4-fold) compared to controls (Fig. 3a–e;
P < 0.05). Live GBS did not change IL-17 secretion
from choriodecidual punches compared to control
(Fig. 3f). LTA significantly increased only IL-8 (2.9-
fold) and TNF-a (11.7-fold), and LPS significantly
increased IL-6 (5.3-fold), IL-8 (3.3-fold), and TNF-a
(33.4-fold). Neither LTA nor LPS stimulated
increased release of IL-1a or IL-1b.
a b
Fig. 2 IL-1b and TNF-a release by
choriodecidual punch cultures treated with
medium alone (control), heat-killed GBS, or
live GBS. IL-1b (a) and TNF-a (b) in the
medium were measured by ELISA. Columns
are mean  S.E.M. (N = 5 women). Asterisks
(*) represent significant differences between
treatment and control when compared by





Fig. 3 Cytokine release into medium by
choriodecidual punch cultures treated with
medium alone (control), live GBS, LTA, or
LPS. IL-1a (a), IL-1b (b), IL-6 (c), IL-8 (d), and
TNF-a (e) in the medium were measured by
ELISA. IL-17 (f) release was measured after
treatment with medium alone (control) or live
GBS. Columns are mean  S.E.M. (N = 21
women for control and live GBS treatment
groups; N = 6 women for LTA and LPS
treatment groups). Asterisks (*) represent
significant differences between treatment and
control when compared by Tukey’s post hoc
test following ANOVA (P < 0.05).
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IL-1 neutralizing antibody and IL-1 receptor
antagonist inhibit GBS choriodecidual conditioned
medium stimulated HBD-2 release from amnion
epithelial cells
To test the hypothesis that IL-1a and IL-1b secreted
from choriodecidua mediates amnion-secreted HBD-
2, amnion epithelial cell cultures were treated with
GBS choriodecidual conditioned medium containing
IL-1b neutralizing antibody or IL-1Ra as inhibitors of
IL-1 signaling. To determine the appropriate concen-
tration of inhibitors, we established concentration-
response curves for each inhibitor in amnion epithelial
cells treated with 1 ng/mL IL-1a or 1 ng/mL IL-1b
(Figs S1 and S2). The IL-1b neutralizing antibody
partially suppressed HBD-2 secretion stimulated by
GBS choriodecidual conditioned medium (1.8-fold
reduction), whereas IL-1Ra almost abolished the
response (9.7-fold reduction) (Fig. 4; P < 0.05). IL-1b
(10 ng/mL) was used as positive control for HBD-2
secretion from amnion epithelial cells.
Recombinant IL-1a and IL-1b stimulate HBD-2
release from amnion epithelial cells
Because experiments with IL-1 inhibitors suggested
a role for IL-1a and IL-1b in the HBD-2 response in
amnion epithelial cells, we treated amnion epithelial
cells with recombinant cytokines (Fig. 5). HBD-2
release was significantly increased in a concentra-
tion-dependent manner by either IL-1a or IL-1b
(Figs 5 and 6; P < 0.05), demonstrating that IL-1a
and IL-1b directly stimulated HBD-2 release. How-
ever, co-treatment with equal concentrations of each
IL-1a and IL-1b did not produce an increased HBD-2
response compared with exposure to either recombi-
nant cytokine alone (Fig. 6). Treatment with recom-
binant cytokines, IL-6, IL-8, IL-17, or TNF-a had no
significant effect on HBD-2 from amnion epithelial
cell cultures (Fig. 5).
Discussion
As one of the leading causes of neonatal morbidity
and mortality, GBS remains a serious public health
problem.1 The mechanisms by which GBS interacts
with the host immune response have yet to be fully
elucidated in gestational tissues. We previously
reported that expression of the antimicrobial peptide
HBD-2 increases in amnion epithelial cells of full
thickness extraplacental membranes following GBS
inoculation on the decidual side of the membranes
in vitro, in the apparent absence of direct contact
with the amnion epithelial cells.15 Zaga-Clavellina,
et al.23 reported similar HBD-2 results in full thick-
ness human extraplacental membranes treated with
GBS. Here, we show for the first time that soluble
factors from GBS-stimulated choriodecidual cultures
were essential for secretion of HBD-2 from the
Fig. 4 The effect of IL-1 inhibitors on HBD-2 release by amnion
epithelial cells. Amnion epithelial cells were treated with
choriodecidual (CD) conditioned medium with and without IL-1
inhibitors for 24 hr. IL-1b (10 ng/mL) treatment for 24 hr was used as
a positive control for HBD-2 secretion from amnion epithelial cells.
HBD-2 protein in the amnion cell culture medium was measured by
ELISA. Columns are mean  S.E.M. (N = 5 women). Pound symbol (#)
represents significant differences between treatment and medium
only control and asterisks (*) represent significant differences
between treatment and GBS CD Medium when compared by Tukey’s
post hoc test following ANOVA (P < 0.05).
Fig. 5 HBD-2 release into medium by primary amnion epithelial cells
treated with recombinant cytokines after 24 hr. HBD-2 protein in the
medium was measured by ELISA. Columns are mean  S.E.M. (N = 3–
6 women). Asterisks (*) represent significant differences between
treatment and control when compared by Tukey’s post hoc test
following ANOVA (P < 0.05).
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amnion, and present evidence that IL-1b may play a
critical role as a soluble factor in the tissue signaling
necessary for the GBS-stimulated HBD-2 response in
amniotic cells.
The present study utilized a combination of
approaches to investigate GBS-stimulated intercellu-
lar signal transduction for increased amniotic expres-
sion of HBD-2. To study contributions specifically
from the choriodecidua, we dissected choriodecidua
from amnion, cultured choriodecidual punches with
various treatments, and then used the sterile-filtered
choriodecidual conditioned media to expose human
amnion epithelial cell cultures. The large increase in
IL-1a and IL-1b in the medium from GBS-treated
choriodecidual tissue cultures suggests that IL-1 may
have a role in GBS-stimulated responses in extra-
placental membranes. Inhibition of stimulated HBD-
2 secretion from amnion epithelial cells using an
IL-1b neutralizing antibody and IL-1Ra, a nonselec-
tive IL-1 receptor antagonist, confirmed a role for
IL-1 in the HBD-2 pathway. As we observed near
complete inhibition of HBD-2 secretion when using
IL-1Ra and only partial inhibition when using IL-1b
neutralizing antibody, IL-1a and IL-1b may have
redundant functions in HBD-2 secretion from
amnion epithelial cells. Because live GBS failed to
stimulate HBD-2 release from cultured amnion
epithelial cells, GBS is not likely the source of the
soluble factors responsible for stimulating HBD-2
release from amnion epithelial cells. Moreover, ster-
ile-filtered supernatant from GBS cultures did not
simulate HBD-2 in amnion epithelial cells in preli-
minary studies (data not shown), consistent with the
conclusion that the choriodecidua, and not GBS, is
the source of the soluble factor(s) necessary for stim-
ulating the HBD-2 response in amnion cells. A simi-
lar mechanism, demonstrating the necessity of IL-1b
in stimulating HBD-2 secretion, has been proposed
for both uterine and pulmonary epithelial cells.24,25
Previous studies suggest that amnion epithelial cells
are incapable of producing IL-1, lending further sup-
port for choriodecidua as the IL-1 source for HBD-2
production in amnion epithelial cells.26,27
Previous studies have shown that both IL-1a and
IL-1b are present in placenta and extraplacental
membranes of healthy women.28–30 We demon-
strated that recombinant IL-1b stimulated HBD-2 in
amnion epithelial cell cultures, consistent with pre-
vious studies.14 In addition, we showed for the first
time that recombinant IL-1a also stimulated HBD-2
secretion in human amnion cells, and did so at con-
centrations similar to IL-1a concentrations detected
in medium of GBS-stimulated choriodecidual tissue
punch cultures. Our results are consistent with
increases in IL-1a reported in bladder tissue and
urine of mice treated with pathogenic GBS.31 Fur-
thermore, IL-1a and IL-1b are implicated in stimu-
lating HBD-2 secretion from other cell and tissue
types including human keratinocytes, uterine macro-
phages, corneal epithelial cells, and middle ear epi-
thelial cells.32–35
Exposure of human amnion epithelial cell cultures
to heat-killed GBS failed to stimulate release of
either IL-1b or TNF-a cytokines, in contrast to the
strong stimulatory response observed with live GBS.
This finding suggests that the GBS response may be
dependent on more than an immunogenic response
to the bacterial cell wall. Consistent with the latter
explanation, neither the gram negative bacterial cell
wall component LPS nor the gram positive bacterial
cell wall component LTA stimulated HBD-2 release
from amnion cell cultures. Likewise, neither LPS nor
LTA stimulated IL-1a or IL-1b release from chorio-
decidual punch cultures. In contrast, both LTA and
LPS-stimulated release of IL-6, IL-8, and TNF-a.
Because IL-1a and IL-1b were the only cytokines
assessed in the present study that required live GBS
for stimulation, and because live GBS was required
for stimulating the HBD-2 response in amnion cells,
these cytokine results lend further, albeit indirect,
support for IL-1a and IL-1b as possible mediators of
GBS signaling for the amniotic HBD-2 response.
Fig. 6 HBD-2 release by amnion epithelial cells treated with
recombinant IL-1a and IL-1b after 24 hr. Equal concentrations of each
cytokine were used for the IL-1a + IL-1b treatment group. HBD-2
protein in the medium was measured by ELISA. Columns are
mean  S.E.M. (N = 7 women). Asterisks (*) represent significant
differences compared to medium only control when compared by
Tukey’s post hoc test following ANOVA (P < 0.05). No statistical
differences were observed between cytokines treatments at any given
concentration.
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Although LTA is most relevant to gram positive
GBS, LPS was included as an additional exposure
because of its widespread use as an immunogenic
stimulus in experiments with gestational tissues.36–38
In our study, bacteria cell wall or membrane com-
ponents LTA and LPS did not stimulate IL-1a or
IL-1b secretion from the choriodecidual tissue. Other
studies have observed an increase in IL-1b secretion
from full thickness extraplacental membranes treated
with LPS.36–39 In contrast to our study which used
only choriodecidual tissue, these studies used full
thickness membranes and the magnitude of the
changes was modest and varied among studies. In
addition, the source and concentration of the LPS we
used was different and could have influenced the
results. In agreement with our study, King, et al.40
found that LPS and LTA had no effect on antimicro-
bial peptide mRNA expression in human endometrial
epithelial cells. Likewise, we observed that heat-
killed GBS failed to elicit IL-1b or TNF-a secretion
from the choriodecidual tissue, suggesting that cyto-
kine stimulation relies on either a heat-liable protein
or internalization of the live bacterium. The latter
results are similar to those showing that live S. aureus
engages inflammatory pathways and cytokine secre-
tion differently than heat-killed S. aureus in mononu-
clear cells.41 Although, not tested here, cellular
internalization of live GBS may be critical for cyto-
kine secretion in our model, as has been demon-
strated previously in mouse dendritic cells.42
Cytokines mediate parturition-activating pathways
by increasing prostaglandins (PGs), matrix metallo-
proteinases, and recruitment of neutrophils and mac-
rophages in the gestational tissues. In particular, IL-1b
has been implicated in adverse birth outcomes.
Recently, Mitchell, et al.43 linked maternal recto-vag-
inal GBS colonization during pregnancy with
increased IL-1b in maternal and fetal serum and early
term births. Non-human primates inoculated with
GBS had increased amniotic fluid concentrations of
IL-1b, as well as IL-6, and TNF-a, PGE2 and PGF2a,
prior to the onset of contractions and parturition.44
Furthermore, direct infusion with IL-1b stimulated
the onset of contractions and preterm labor in pri-
mates.45 Fewer studies have examined the role of IL-
1a in adverse birth outcomes. One study found that
IL-1a treated pregnant mice had increased PGE2 and
fetal deaths.46
Although recombinant IL-1a and IL-1b each stim-
ulated HBD-2 release in amnion epithelial cells, other
cytokines (IL-6, IL-8, IL-17, and TNF-a) did not sig-
nificantly increase HBD-2 secretion. The concentra-
tions of IL-6, IL-17, and TNF-a we used to treat
amnion epithelial cells were higher than the concen-
trations we observed in the medium of the GBS-stim-
ulated choriodecidual punch cultures. IL-17 is
secreted from Th17 cells and implicated in HBD-2
secretion in pulmonary epithelium and keratino-
cytes.47–49 Although IL-17 appears to produce a slight
increase in HBD-2 (not statistically significant) in our
amnion epithelial cells, no IL-17 was detected when
choriodecidual punches were treated with GBS. As
IL-17 was not elevated in the choriodecidual punches
treated with GBS, we did not test the ability of LTA
or LPS to stimulate IL-17. Regardless, IL-17 does not
appear to be an important immune mediator of
HBD-2 release in human extraplacental membranes
ex vivo and is likely because of minimal immune cells
present in the healthy tissue we collect.
While contributing new information to the under-
standing of microbial infection in gestational tissue,
our study has limitations, nonetheless. Because we
did not directly assess microbial contamination of the
donor tissue, it is possible that the tissues used in
these experiments had GBS or other microbial con-
tamination. However, no microbial growth was
observed and cytokine levels in the medium
remained low in no-treatment controls, suggesting
that infection was not present prior to treatment.50
In addition, the women donors received antibiotics
prior to cesarean section surgery, as is practice at the
University of Michigan hospitals, and antibiotics were
present in medium for an initial 4-hr culture period.
Using the same tissue collection and culture protocols
as in the present study, we did not observe microbial
growth from extraplacental tissue extracts in agar.15
Furthermore, our data clearly show that GBS, LTA,
and LPS elicit-specific robust cellular responses.
In conclusion, this study utilized human extraplac-
ental membranes to show that GBS-treated chorio-
decidual tissue secrete IL-1a and IL-1b. Furthermore,
we show that IL-1a and IL-1b from the choriodeci-
dual tissues are important for GBS-stimulated HBD-2
secretion from the amnion epithelial cells.
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